A Soluble Activin Receptor Type IIB Does Not Improve Blood Glucose in Streptozotocin-Treated Mice
| Autor: | Tingqing Guo, Jennifer Portas, Alexandra C. McPherron, Qian Wang |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2015 |
| Předmět: |
Blood Glucose
Male medicine.medical_specialty endocrine system diseases type 1 diabetes Activin Receptors Type II Myostatin Biology activin receptor Applied Microbiology and Biotechnology Streptozocin Muscle hypertrophy Mice Insulin resistance Muscular Diseases Internal medicine Diabetes mellitus medicine Animals muscle hypertrophy Molecular Biology Ecology Evolution Behavior and Systematics nutritional and metabolic diseases Cell Biology Activin receptor Streptozotocin medicine.disease Recombinant Proteins Mice Inbred C57BL Endocrinology Diabetes Mellitus Type 1 biology.protein glucocorticoid Glucocorticoid ACVR2B Developmental Biology medicine.drug Research Paper |
| Zdroj: | International Journal of Biological Sciences |
| ISSN: | 1449-2288 |
| Popis: | Type 1 diabetes mellitus (T1DM), or insulin dependent DM, is accompanied by decreased muscle mass. The growth factor myostatin (MSTN) is a negative regulator of muscle growth, and a loss of MSTN signaling has been shown to increase muscle mass and prevent the development of obesity, insulin resistance and lipodystrophic diabetes in mice. The effects of MSTN inhibition in a T1DM model on muscle mass and blood glucose are unknown. We asked whether MSTN inhibition would increase muscle mass and decrease hyperglycemia in mice treated with streptozotocin (STZ) to destroy pancreatic beta cells. After diabetes developed, mice were treated with a soluble MSTN/activin receptor fused to Fc (ACVR2B:Fc). ACVR2B:Fc increased body weight and muscle mass compared to vehicle treated mice. Unexpectedly, ACVR2B:Fc reproducibly exacerbated hyperglycemia within approximately one week of administration. ACVR2B:Fc treatment also elevated serum levels of the glucocorticoid corticosterone. These results suggest that although MSTN/activin inhibitors increased muscle mass, they may be counterproductive in improving health in patients with T1DM. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|